Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 5 - October 2018
  3. 51st annual Meeting ESPGHAN
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 5 - October 2018
  3. 51st annual Meeting ESPGHAN
Gastroenterology

51st annual Meeting ESPGHAN

Drug

Congress review

By Dr. Solange Heller Rouassant
Pediatrician with specialty in Pediatric Gastroenterology and Nutrition México City, México Mexican Councilor of NASPGHAN

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

About this article

Created 26 August 2021
Updated 28 September 2021

Gastric microbiota and Helicobacter pylori

Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, and Fusobacteria are the most abundant phyla in H. pylori positive and H.pylori-negative patients and this gastric microbiota may play a role in the H. pylori-associated carcinogenicity [1]. Alarcón [2] characterized gastric microbiota in children with and without H. pylori; when detected, H. pylori dominated the microbial community, but when absent, there was a higher bacterial richness and diversity.

Gut microbiota in early life

Development of gut microbiota in early life is influenced by delivery mode, breast milk or formula feeding, antibiotic use, timing of introduction of solid foods and cessation of milk feeding. The gut microbiota of a newborn is transiently dominated by Enterobacteriaceae and Staphylococcus and very soon by Bifidobacterium and lactic acid bacteria. Bifidobacterium-dominated microbiota continues until complementary feeding starts [3].

  • Dukanovic [4] showed that C-section delivery and exclusive breast-feed infants have a relatively low abundance of Bacteroides in the infant stool; Bacteroides species were detected in 73% vaginal and 16% C-section samples.

  • Collado [4] demonstrated shared features between microbiota in maternal-infant pair and breast milk, suggesting a microbial transfer during lactation. Specific strains of Bacteroides, Bifidobacterium, Staphylococcus and Enterococcus genera were isolated from maternal infant gut and specific strains of Staphylococcus, Lactobacillus, Enterobacter and Acinetobacter from paired breast milk at 2 months of age.

Probiotics and synbiotics supplementation in early life

  • It has been reported that association between gut microbiota composition in early life and development of diseases exists [5]. Studies on early infant gut microbiome have shown that antibiotic resistant gene carriage is acquired early and may have long term sequelae.

  • Exclusively breastfed infants were supplemented with Bifidobacterium longum subsp. infantis (Casaburi [4]) as a targeted probiotic capable of remodeling gut microbiome with potential reduction of antibiotic gene reservoirs. It was concluded that colonization of high levels of this strain is a safe and non-invasive method to decrease a reservoir of genes that confer antibiotic resistance.

  • High levels of Bifidobacterium longum subsp. infantis in breast-fed infants, regardless of delivery mode, remained stable through the first year of life if breastfeeding was continued [4].

Infant formula supplementation with prebiotics and probiotics

Human milk oligosaccharides (HMOs) are unconjugated, solid and abundant compounds breast milk. The spectrum of HMOs in mother’s milk especially related to the mother’s secretor status modulates the bifidobacterial composition of the infant’s gut.

Gut of formula-fed infants has a lower relative abundance of Bifidobacteria and a higher microbial diversity. The use of prebiotics in infant formula increases the bifidobacterial fraction in the infant’s gut. Currently, available prebiotics (galacto- (GOS) and fructooligosaccharides (FOS)) are metabolized by Bifidobacteria, but not by the human host [5].

  • Puccio [6] supplemented an infant formula with 2 “fucosyllactose and lacto-N-neotetraose”, commonly found in human milk, with good results. An infant formula with GOS, FOS and Bifidobacterium breve compensates the delayed Bifidobacterium colonization in C-section-delivered infants, modulates gut microbiota and emulates conditions observed in vaginally born infants [6].

  • Comparison of two different infant formula supplemented with prebiotics only or prebiotics and probiotics showed similar gut microbiota profiles than breast-fed infants (Tims & Phavichir [4]).

Cow's milk allergy (CMA) prevention and management

  • Probiotics have been recommended for prevention of CMA even though more evidences are needed. Lactobacillus rhamnosus or Bifidobacterium lactis were administered daily from 35 weeks gestation to 6 months postpartum in mothers, and from birth until the age of two in children. Children that ingested Lactobacillus rhamnosus had a significant reduction of prevalence of eczema in childhood (Wickens [4]).

  • Extensive hydrolyzed infant formulas have been supplemented with L. rhamnosus for the management of IgE mediated CMA and development of immune tolerance. Clinical studies in healthy infants and infants suffering CMA showed that synbiotic-supplemented aminoacid-formulas (AAF) are hypoallergenic, well tolerated, and warranty normal growth.

  • Results of a multicenter, double blind, randomized controlled trial in infants with non IgE mediated CMA was presented (Candy [7]). Infants received a hypoallergenic, AAF formula containing a prebiotic blend of chicory-derived neutral oligofructose and long-chain Bifidobacterium breve . At week 8, significant differences on gut microbiota composition were present between groups, with higher percentages of Bifidobacteria in the symbiotic-AAF supplemented group. Modulation of gut microbiota using specific synbiotics may improve symptoms in infants with CMA.

Infantile colic

Evidence suggests that altered gut microbiota affects gut motor function and induce gas production in infants, resulting in abdominal pain/colic. Manipulation of gut microbiota may play a role in the management and prevention of infantile colic.

  • A Cochrane systematic review [4] of prophylactic probiotics in infantile colic included studies of Lactobacillus reuteri, multi-strain probiotics, Lactobacillus rhamnosus, Lactobacillus paracasei and Bifidobacterium animalis. This meta-analysis showed no differences in the use of several probiotics on primary outcome. However, a wider analysis suggested efficacy of probiotics for infantile colic (Ong [4]).
Sources

1 Llorca L, Pérez-Pérez G, Urruzuno P, et al. Characterization of the gastric microbiota in a pediatric population according to helicobacter pylori status. Pediatr Infect Dis J 2017; 36: 173-8.

2 Alarcón T, Llorca L, Perez-Perez G. Impact of the microbiota and gastric disease development by Helicobacter pylori. Curr Top Microbiol Immunol 2017; 400: 253-75.

3 Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int 2017; 66: 515-22.

4 51st ESPGHAN Annual Meeting. J Pediat Gastroent Nutr 2018; 66 (Supl 2): 1-1177.

5 Jensen ET, Bertelsen RJ, Ringel-Kulka T. Microbiota of the gastrointestinal tract in infancy. In: Floch MH, Ringel Y, Walker WA (eds). The Microbiota in Gastrointestinal Pathophysiology. Amsterdam: Elsevier, 2017, pp. 27-35.

6 Puccio G, Alliet P, Cajozzo C, et al. Effects of infant formula with human milk oligosaccharides on growth and morbidity: A randomized multicenter trial. J Pediatr Gastroent Nutr 2017; 64: 624-31.

7 Candy DCA, Van Ampting MTJ, Oude Nijhuis MM, et al. A synbiotic-containing amino-acid-based formula improves gut microbiota in non-IgE-mediated allergic infants. Pediatr Res 2018; 83: 677-86.

Tags
Gastroenterology Pediatrics H Pylori Probiotics ESPGHAN

en_view en_sources

    Focus
    Microbiota 5 - October 2018
    • Overview
      • The gut microbiome and neurodegeneration
    • Commented articles
      • The food additive trehalose increases the virulence of epidemic clostridium difficile
      • Gut microbiota profiles in untreated children with attention deficit hyperactivity disorder
    • Congress review
      • 51st annual Meeting ESPGHAN
      • 3rd meeting of the federation of neurogastroenterology
    • Press review
      • Microbiota and non-antibiotic drugs interactions: friends or foes?
      • Microbiota and cystic fibrosis
    Created 26 August 2021
    Updated 28 September 2021

    About this article

    To know more about this topic.

    Main topic

    Drug

    Content type

    Congress review
    Gut microbiota profiles in untreated children with attention deficit hyperactivity disorder
    3rd meeting of the federation of neurogastroenterology
    Focus

    Microbiota 5 - October 2018

    Overview

    The gut microbiome and neurodegeneration

    Commented articles

    The food additive trehalose increases the virulence of epidemic clostridium difficile Gut microbiota profiles in untreated children with attention deficit hyperactivity disorder

    Congress review

    51st annual Meeting ESPGHAN 3rd meeting of the federation of neurogastroenterology

    Press review

    Microbiota and non-antibiotic drugs interactions: friends or foes? Microbiota and cystic fibrosis

    Continue reading

    News
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article

    Xpeer course: Detection, Prevention and Treatment of Gut Microbiome Dysbiosis

    Find out more
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    The psychobiotic diet: modulating gut microbiota to reduce stress
    13.02.2023

    The psychobiotic diet: modulating gut microbiota to reduce stress

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo